dc.contributor
Institut Català de la Salut
dc.contributor
[Massó-Vallés D] Peptomyc, Barcelona, Spain. [Soucek L] Peptomyc, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Massó Vallés, Daniel
dc.contributor.author
Soucek, Laura
dc.date.accessioned
2025-10-25T05:39:36Z
dc.date.available
2025-10-25T05:39:36Z
dc.date.issued
2021-09-01T10:59:26Z
dc.date.issued
2021-09-01T10:59:26Z
dc.date.issued
2020-04-04
dc.identifier
Massó-Vallés D, Soucek L. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020 Apr 4;9(4):883.
dc.identifier
https://hdl.handle.net/11351/6251
dc.identifier
10.3390/cells9040883
dc.identifier
000535559500094
dc.identifier.uri
http://hdl.handle.net/11351/6251
dc.description.abstract
Inhibició de Myc; Càncer; Omomyc
dc.description.abstract
Inhibición de myc; Cáncer; Omomyc
dc.description.abstract
Myc inhibition; Cancer; Omomyc
dc.description.abstract
First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein—following the surprising discovery of its cell-penetrating capacity—constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic.
dc.description.abstract
This research was funded by the European Commission (SME Instrument, Grant no. 872212), the Instituto de Salud Carlos III (FIS grant no. PI16-01224) and the European Research Council (CoG grant no. 617473).
dc.format
application/pdf
dc.relation
https://www.mdpi.com/2073-4409/9/4/883
dc.relation
info:eu-repo/grantAgreement/EC/H2020/872212
dc.relation
info:eu-repo/grantAgreement/ES/PE2013-2016/PI16/2F01224
dc.relation
info:eu-repo/grantAgreement/EC/H2020/617473
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Càncer - Tractament
dc.subject
Fosfoproteïnes - Inhibidors
dc.subject
DISEASES::Neoplasms
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Basic Helix-Loop-Helix Transcription Factors::Proto-Oncogene Proteins c-myc
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::neoplasias
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de unión al ADN::factores de transcripción con hélice-asa-hélice básico::proteínas protooncogénicas c-myc
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
